PTO/SB/26 (09-08)

Approved for use through 103 (2006. DBMS) and Approved for use throu

REJECTION OVER A "PRIOR" PATENT	39262/256238
In re Application of: J. Charles Taylor, et al.	
Application No.: 09/827,252	
Filed: April 5, 2001	
For: ORTHOPAEDIC FIXATION PLATE	
except as provided below, the terminal part of the statutory term of any patient granted on the instant the expiration date of the full statutory term prior patient No. 5728,095. — as the term of said and 173, and as the term of said prior patient is presently shortened by any patient granted on the instant application shall be enforceable only for and during such period hat it and the granted on the Instant application and is briding upon the granted as granted on the Instant application and is briding upon the granted, its in making the above disclaiment, he would explain a grant the term of any patient would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the patient is presently shortened by any terminal disclaimer," in the event that said prior patient laise: expires for failure to pay a maintenance fee; is held unenforceable; is found invalid by a court of competent jurisdiction; is statutorly disclaimed in whole or terminally disclaimed under 37 CFR 1.321; has all dains canceled by a reexamination certificate; is reissued; or the supplication of the expiration of its full statutory term as presently shortened it is nany manner terminated prior to the expiration of its full statutory term as presently shortened it is nany manner terminated prior to the expiration of its full statutory term as presently shortened it.	prior patent is defined in 35 U.S.C. 15 where hereby agrees that any patents worker hereby agrees that any patents worker patent are commonly owned. This uccessors or assigns. 1 granted on the instant application that prior patent, "as the term of said prior
Check either box 1 or 2 below, if appropriate.	
 For submissions on behalf of a business/organization (e.g., corporation, partnership, university etc.), the undersigned is empowered to act on behalf of the business/organization. 	government agency,
I hereby declare that all statements made herein of my own knowledge are true and that all belief are believed to be true; and further that these statements were made with the knowledge that made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United statements may jeopardize the validity of the application or any patent issued thereon.	willful folco ototomonia and the liter
The undersigned is an attorney or agent of record. Reg. No. 58,961	
Penae abailey	October 28, 2008 Date
V	
Renae A. Bailey Typed or printed name	
-	404-815-6500 Telephone Number
✓ Terminal disclaimer fee under 37 CFR 1.20(d) included.	rolephone realised
WARNING: Information on this form may become public. Credit card informat be included on this form. Provide credit card information and authorization o	tion should not n PTO-2038.
Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner), orm PTO/SB/96 may be used for making this certification. See MPEP § 324.	
his collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is	e public which is to file (and by the USPTO estimated to take 12 minutes to complete

including gathering, preparing, and submitting the completed support of the Control of the Contr

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 350 LSC. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- 1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S. C. 52) and the Privacy Act (5 U.S. C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing coursel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended. Oursulant to 5 U.SC. 5524/m.
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conduced by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about Individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.